GnRH Antagonist Protects Ovarian Function During Chemotherapy

REFERENCE: O-144KATE STERN, Royal Women’s Hospital, Melbourne A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke with Kate Stern and heard more about the study.